CompletedPhase 3NCT00511147
IGIV Study for Chronic ITP Patients Ages 3-70
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grifols Biologicals, LLC
- Principal Investigator
- Ali Khojasteh, MDCapitol Comprehensive Cancer Care Clinic
- Intervention
- IGIV3I Grifols 10%(biological)
- Enrollment
- 64 enrolled
- Eligibility
- 3-70 years · All sexes
- Timeline
- 2008 – 2014
Study locations (30)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Scottsdale Medical Specialists, Scottsdale, Arizona, United States
- Arizona Oncology Associates, Tucson, Arizona, United States
- Scripps Cancer Center, La Jolla, California, United States
- Kenmar Research Institute, LLC, Los Angeles, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Connecticut Children's Medical Center, Hartford, Connecticut, United States
- Cancer Center of Central Connecticut, Southington, Connecticut, United States
- Georgetown University, Washington D.C., District of Columbia, United States
- VA Medical Center, Washington D.C., District of Columbia, United States
- Halifax Health Medical Center, Daytona Beach, Florida, United States
- Hematology Oncology Associates, Lake Worth, Florida, United States
- Lakeland Regional Cancer Center, Tampa, Florida, United States
- St. Joseph's Children's Hospital of Tampa, Tampa, Florida, United States
- Cleveland Clinic Florida, Weston, Florida, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Instituto Grifols, S.A.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00511147 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation